Literature DB >> 22244659

Genetic risk and gynecologic cancers.

Laura L Holman1, Karen H Lu.   

Abstract

Although most gynecologic malignancies are sporadic, hereditary cancer syndromes cause a substantial portion of these cancers. Given that the diagnosis of these syndromes has prognostic and therapeutic implications for the patient, as well as preventive implications for her family members, genetic testing is now an accepted part of the management of the patient who has gynecologic cancer.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh：

Year:  2012        PMID： 22244659      PMCID： PMC5134904          DOI： 10.1016/j.hoc.2011.11.003

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  102 in total

1.  Radical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary development.

Authors:  Eric Leblanc; Fabrice Narducci; Isabelle Farre; Jean-Philippe Peyrat; Sophie Taieb; Claude Adenis; Philippe Vennin
Journal:  Gynecol Oncol       Date:  2011-03-15       Impact factor: 5.482

2.  Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  Noah D Kauff; Jaya M Satagopan; Mark E Robson; Lauren Scheuer; Martee Hensley; Clifford A Hudis; Nathan A Ellis; Jeff Boyd; Patrick I Borgen; Richard R Barakat; Larry Norton; Mercedes Castiel; Khedoudja Nafa; Kenneth Offit
Journal:  N Engl J Med       Date:  2002-05-20       Impact factor: 91.245

3.  Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study.

Authors:  Andrea Eisen; Jan Lubinski; Jan Klijn; Pal Moller; Henry T Lynch; Kenneth Offit; Barbara Weber; Tim Rebbeck; Susan L Neuhausen; Parviz Ghadirian; William D Foulkes; Ruth Gershoni-Baruch; Eitan Friedman; Gadi Rennert; Teresa Wagner; Claudine Isaacs; Charmaine Kim-Sing; Peter Ainsworth; Ping Sun; Steven A Narod
Journal:  J Clin Oncol       Date:  2005-10-20       Impact factor: 44.544

4.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

5.  Barriers to participating in genetic counseling and BRCA testing during primary treatment for breast cancer.

Authors:  Kathryn J Schlich-Bakker; Herman F J ten Kroode; Carla C Wárlám-Rodenhuis; Jan van den Bout; Margreet G E M Ausems
Journal:  Genet Med       Date:  2007-11       Impact factor: 8.822

6.  Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.

Authors:  Susan M Domchek; Tara M Friebel; Susan L Neuhausen; Theresa Wagner; Gareth Evans; Claudine Isaacs; Judy E Garber; Mary B Daly; Rosalind Eeles; Ellen Matloff; Gail E Tomlinson; Laura Van't Veer; Henry T Lynch; Olufunmilayo I Olopade; Barbara L Weber; Timothy R Rebbeck
Journal:  Lancet Oncol       Date:  2006-03       Impact factor: 41.316

7.  Histopathologic features of genetically determined ovarian cancer.

Authors:  P A Shaw; J R McLaughlin; R P Zweemer; S A Narod; H Risch; R H M Verheijen; A Ryan; F H Menko; P Kenemans; I J Jacobs
Journal:  Int J Gynecol Pathol       Date:  2002-10       Impact factor: 2.762

8.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.

Authors:  Magali Olivier; David E Goldgar; Nayanta Sodha; Hiroko Ohgaki; Paul Kleihues; Pierre Hainaut; Rosalind A Eeles
Journal:  Cancer Res       Date:  2003-10-15       Impact factor: 12.701

9.  Ovarian cancer in younger vs older women: a population-based analysis.

Authors:  J K Chan; R Urban; M K Cheung; K Osann; J Y Shin; A Husain; N N Teng; D S Kapp; J S Berek; G S Leiserowitz
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

10.  Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study.

Authors:  Fabrice Lécuru; Ulrike Metzger; Catherine Scarabin; Marie Aude Le Frère Belda; Sylviane Olschwang; Pierre Laurent Puig
Journal:  Fam Cancer       Date:  2007-04-06       Impact factor: 2.446
View more
  1 in total

1.  NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.

Authors:  Elena Sultova; C Benedikt Westphalen; Andreas Jung; Joerg Kumbrink; Thomas Kirchner; Doris Mayr; Martina Rudelius; Steffen Ormanns; Volker Heinemann; Klaus H Metzeler; Philipp A Greif; Alexander Burges; Fabian Trillsch; Sven Mahner; Nadia Harbeck; Rachel Wuerstlein
Journal:  Arch Gynecol Obstet       Date:  2020-12-04       Impact factor: 2.344
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.